Is Bluebird Bio Stock a Good Investment?
Bluebird Bio Investment Advice | BLUE |
- Examine Bluebird Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bluebird Bio's leadership team and their track record. Good management can help Bluebird Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Bluebird Bio's business and its evolving consumer preferences.
- Compare Bluebird Bio's performance and market position to its competitors. Analyze how Bluebird Bio is positioned in terms of product offerings, innovation, and market share.
- Check if Bluebird Bio pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bluebird Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bluebird bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bluebird bio is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bluebird Bio Stock
Researching Bluebird Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 44.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bluebird bio has Price/Earnings To Growth (PEG) ratio of 0.32. The entity recorded a loss per share of 1.8. The firm had not issued any dividends in recent years. Bluebird Bio had 1544:1000 split on the 5th of November 2021.
To determine if Bluebird Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bluebird Bio's research are outlined below:
| Bluebird bio generated a negative expected return over the last 90 days | |
| Bluebird bio has high historical volatility and very poor performance | |
| Bluebird bio has some characteristics of a very speculative penny stock | |
| Bluebird bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.5 M. Net Loss for the year was (211.91 M) with loss before overhead, payroll, taxes, and interest of (247.24 M). | |
| Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bluebird bio has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Bluebird Bios SWOT analysis gene therapy firm faces cash crunch amid launch |
Bluebird Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bluebird bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bluebird Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bluebird Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bluebird Bio's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.36 | -0.31 | 0.05 | 13 | ||
2024-05-09 | 2024-03-31 | -0.41 | -0.36 | 0.05 | 12 | ||
2013-11-14 | 2013-09-30 | -0.2 | -0.26 | -0.06 | 30 | ||
2024-08-14 | 2024-06-30 | -0.34 | -0.42 | -0.08 | 23 | ||
2014-08-12 | 2014-06-30 | -0.45 | -0.54 | -0.09 | 20 | ||
2015-02-25 | 2014-12-31 | -0.57 | -0.67 | -0.1 | 17 | ||
2014-11-12 | 2014-09-30 | -0.5 | -0.6 | -0.1 | 20 | ||
2014-05-13 | 2014-03-31 | -0.31 | -0.44 | -0.13 | 41 |
Know Bluebird Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bluebird Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bluebird bio backward and forwards among themselves. Bluebird Bio's institutional investor refers to the entity that pools money to purchase Bluebird Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 1.3 M | Bank Of America Corp | 2024-06-30 | 1.3 M | Deutsche Bank Ag | 2024-06-30 | 1.2 M | Jane Street Group Llc | 2024-06-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1 M | Masters Capital Management Llc | 2024-09-30 | 975 K | Woodline Partners Lp | 2024-06-30 | 969.3 K | Susquehanna International Group, Llp | 2024-06-30 | 901.9 K | Blackrock Inc | 2024-06-30 | 15.4 M | Vanguard Group Inc | 2024-09-30 | 10.5 M |
Bluebird Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.07 M.Market Cap |
|
Bluebird Bio's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.09) | (1.03) |
Determining Bluebird Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Bluebird Bio is a good buy. For example, gross profit margin measures Bluebird Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bluebird Bio's profitability and make more informed investment decisions.
Please note, the presentation of Bluebird Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bluebird Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bluebird Bio's management manipulating its earnings.
Evaluate Bluebird Bio's management efficiency
Bluebird bio has return on total asset (ROA) of (0.3624) % which means that it has lost $0.3624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.867) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio's management efficiency ratios could be used to measure how well Bluebird Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Bluebird Bio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 10.8 M, whereas Other Assets are forecasted to decline to about 33.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.77 | 1.68 | |
| Tangible Book Value Per Share | 1.62 | 1.54 | |
| Enterprise Value Over EBITDA | (1.56) | (1.63) | |
| Price Book Value Ratio | 0.78 | 0.46 | |
| Enterprise Value Multiple | (1.56) | (1.63) | |
| Price Fair Value | 0.78 | 0.46 | |
| Enterprise Value | 380.2 M | 386.4 M |
Bluebird bio benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 0.803 |
Basic technical analysis of Bluebird Stock
As of the 25th of November, Bluebird Bio shows the Risk Adjusted Performance of (0.12), standard deviation of 5.27, and Mean Deviation of 3.95. Bluebird bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Bluebird bio market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Bluebird bio is priced correctly, providing market reflects its regular price of 0.35 per share. As Bluebird bio appears to be a penny stock we also recommend to validate its jensen alpha numbers.Bluebird Bio's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluebird Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluebird Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bluebird Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Colvin Richard A over three months ago Disposition of 2343 shares by Colvin Richard A of Bluebird Bio at 2.9769 subject to Rule 16b-3 | ||
Sterling O. James over three months ago Acquisition by Sterling O. James of 300000 shares of Bluebird Bio at 0.98 subject to Rule 16b-3 | ||
Cloonan Michael over three months ago Insider Trading | ||
Jeffrey Walsh over six months ago Sale by Jeffrey Walsh of 300 shares of Bluebird Bio | ||
Jeffrey Walsh over six months ago Exercise or conversion by Jeffrey Walsh of 100 shares of Bluebird Bio subject to Rule 16b-3 | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 200 shares of Bluebird Bio | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 100 shares of Bluebird Bio |
Bluebird Bio's Outstanding Corporate Bonds
Bluebird Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bluebird bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bluebird bonds can be classified according to their maturity, which is the date when Bluebird bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Bluebird Bio's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bluebird Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 3.95 | |||
| Coefficient Of Variation | (611.00) | |||
| Standard Deviation | 5.27 | |||
| Variance | 27.8 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.10) | |||
| Total Risk Alpha | (1.70) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 23.25 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 7.02 | |||
| Skewness | 0.093 | |||
| Kurtosis | 1.49 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 3.95 | |||
| Coefficient Of Variation | (611.00) | |||
| Standard Deviation | 5.27 | |||
| Variance | 27.8 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.10) | |||
| Total Risk Alpha | (1.70) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 23.25 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 7.02 | |||
| Skewness | 0.093 | |||
| Kurtosis | 1.49 |
Consider Bluebird Bio's intraday indicators
Bluebird Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bluebird Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bluebird Bio time-series forecasting models is one of many Bluebird Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bluebird Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Bluebird Stock media impact
Far too much social signal, news, headlines, and media speculation about Bluebird Bio that are available to investors today. That information is available publicly through Bluebird media outlets and privately through word of mouth or via Bluebird internal channels. However, regardless of the origin, that massive amount of Bluebird data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bluebird Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bluebird Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bluebird Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bluebird Bio alpha.
Bluebird Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bluebird Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bluebird Bio Corporate Management
| Mr MD | Chief Officer | Profile | |
| Melissa Bonner | VP Research | Profile | |
| Andrea Walton | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Christopher CPA | Principal CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bluebird Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.